About this historical patient account: The information below describes reported observations from one case. It does not establish treatment efficacy, safety, a causal relationship or an expected outcome. Outcomes vary, and reported improvement does not demonstrate cure. Do not change prescribed medicines or delay established care based on this account.

Intervention context: This account does not establish that the cell, growth-factor or other biological interventions described are approved or effective for this diagnosis. Some may be investigational. A qualified specialist should explain the current evidence, regulatory status, alternatives, uncertainties and risks before any treatment decision.

Patient Information:

• Name: Guido Rico Agreda
• Diagnosis: Metastatic Adenocarcinoma of Colon
• Date of Birth (D.O.B): August 31, 1942
• Gender: Male
• Country: Bolivia

Treatment: Comprehensive Treatment at Beijing Puhua International Hospital for Metastatic Adenocarcinoma of Colon, including:

• Radio-Frequency Ablation (RFA)
• Systemic Chemotherapy (Capecitabine)
• Cytokine-Induced Killer Cells (CIK Cell) Therapy
• Traditional Chinese Medicine (TCM)

Medical History before Admission:

73-year-old male patient, Mr. Guido Rico Agreda:

• Underwent right semi-colectomy in 2006 for moderately-differentiated adenocarcinoma of the colon with positive lymph node involvement (+1/20), Dukes C.
• Completed adjuvant chemotherapy (12 cycles of 5-FU and LV civ48hs)
• Experienced progressive enlargement of peritoneal lymph nodes, necessitating excision in 20XX
• Undergone Radio-Frequency Ablation (RFA) for liver metastases

Treatment Details at Beijing Puhua International Hospital:

Radio-Frequency Ablation (RFA):

• Two procedures performed on September 15 and 29, 20XX respectively.
• Each procedure involved ablating two liver lesions using multi-electrode needles heated to 90°C for varying durations (10-15 minutes).
• Local injections of interleukin-2 (1,000,000 IU) and GM-CSF (150 µg) were administered post-procedure.
• Patient tolerated procedures well with no complications.

Systemic Chemotherapy:

• Capecitabine 825-1000mg/m² Bid, D1-14

Immunotherapy & Traditional Chinese Medicine (TCM):

• Cytokine-Induced Killer Cells (CIK cells) therapy administered twice during admission
• Acupuncture and Chinese herbal therapy as supportive interventions described in the report; reduced toxicity or treatment benefit is not established by this case

Medical Condition after Treatment:

Upon discharge, Mr. Agreda's physical condition showed continued improvement with no discomfort experienced throughout his treatment. The historical account reports an estimate of tumor necrosis after RFA. The assessment method and longer-term outcome are not provided here, so the claim should not be treated as a quantified treatment benefit or expected response. Optimal response evaluation via repeat CT or PET-CT scan recommended around one month post-treatment.

Post-Operative:

Mr. and Mrs. Agreda expressed high satisfaction with the cancer treatment and services provided at Beijing Puhua International Hospital. Mr. Agreda willingly shared his treatment experiences to benefit prospective patients.